Will PEDF Therapy Reverse Chronic Demyelination and Prevent Axon Loss in a Murine Model of Progressive Multiple Sclerosis
Abstract
The purpose of this project was to assess the potential of pigment epithelium-derived factor (PEDF) as a therapy to enhance central nervous system (CNS) remyelination and preserve CNS axons in mouse models of multiple sclerosis models. After determining the dosage of recombinant PEDF required to obtain a plateau stimulatory effect on post-lysolecithin CNS remyelination, we demonstrated that intraventricular infusion of recombinant PEDF accelerated CNS oligodendroglial recruitment from both subventricular zone neural progenitor cells and from oligodendroglial progenitor cells (OPCs), and accelerated corpus callosum remyelination. We also demonstrated that cuprizone elicited more profound corpus callosum demyelination and slower remyelination in constitutive PEDF knockout mice than in wild-type mice. In chronic experimental autoimmune encephalomyelitis (EAE) elicited by immunization with a myelin oligodendrocyte glycoprotein (MOG) peptide, intravenous, but not intraventricular, administration of PEDF diminished severity of neurological deficits.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2015
- Accession Number
- AD1006805
Entities
People
- David Pleasure
Organizations
- University of California, Davis